Abcellera Biologics Inc. revenue
Abcellera Biologics Inc.'s revenue was $75.1m in fiscal 2025, up 160.6% on the year before. Since fiscal 2019 ($11.6m) it has grown at a compound 36.5% a year. Over the last twelve months it was $66.2m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Licenses | $46.9M | 62.5% | ▲ 4372.8% |
| Research Fees | $27.2M | 36.2% | ▲ 3.5% |
| Milestone Payments | $1M | 1.3% | ▼ 33.3% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| Canada | $64M | 85.2% | ▲ 144.3% |
| United States | $11.1M | 14.8% | ▲ 311.1% |
From Abcellera Biologics Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Abcellera Biologics Inc. | $66.2m | 101.3% | -23.0% |
| Cytokinetics Inc | $67.7m | -21.1% | 89.5% |
| Clinuvel Pharmaceuticals Ltd | $64.3m | 5.2% | — |
| Recursion Pharmaceuticals, Inc. | $68.2m | 56.2% | 12.9% |
| Wave Life Sciences, Inc. | $70.9m | 202.3% | 20.7% |
| Viridian Therapeutics, Inc.\de | $71.1m | 23220.3% | 264.4% |
Compare with peers
- Cytokinetics Inc revenue
- Clinuvel Pharmaceuticals Ltd revenue
- Recursion Pharmaceuticals, Inc. revenue
- Wave Life Sciences, Inc. revenue
- Viridian Therapeutics, Inc.\de revenue
Head to head: ABCL vs CYTKABCL vs CUVLABCL vs RXRX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies